异源序贯免疫策略下四价减毒登革疫苗的免疫原性:1期随机临床试验
该1期首次人体异源序贯免疫研究将80名志愿者分为4组,分别按不同顺序和间隔(28或180天)接种四价登革纯化灭活疫苗(TDENV-PIV,含铝佐剂)与四价登革减毒活疫苗(TDENV-LAV)。所有方案安全性可接受,无疫苗相关严重不良事件;TDEN-PIV后接TDEN-LAV较反向顺序诱导更高的中和抗体滴度和四价血清转换率,两个序贯组在加强后28天均达100%四价血清转换,多数受试者维持至第180天。
要点
- TDENV-PIV后接TDENV-LAV较反向顺序诱导更高中和抗体与四价血清转换率。
- 所有方案安全性可接受,无疫苗相关严重不良事件。
- 异源序贯登革疫苗策略值得进一步评估安全性与免疫原性。
核心结论
- 异源序贯免疫策略用于登革疫苗值得进一步评估安全性、免疫原性和潜在临床获益。
研究设计与样本
- 1期首次人体异源序贯免疫研究,80名志愿者分为4组,按不同顺序和间隔(28或180天)接种TDENV-PIV(含铝佐剂)与TDENV-LAV。
主要发现
- 所有疫苗接种方案安全性可接受,无疫苗相关严重不良事件。
- TDENV-PIV后接TDENV-LAV较TDENV-LAV后接TDENV-PIV诱导更高的中和抗体滴度和更高的四价血清转换率。
- TDENV-PIV后接TDENV-LAV的两个组在加强剂量后28天均达100%四价血清转换,多数受试者维持至第180天。
关键数值与推荐
- TDENV-PIV后接TDENV-LAV的两个组在加强后28天四价血清转换率为100%。
临床怎么用
- 提示登革疫苗研发中异源序贯策略(灭活后接减毒)可能优于反向顺序,但尚需进一步评估。
局限性
- 为1期首次人体研究,样本量80人,需进一步评估安全性与免疫原性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is a global health problem and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime-boost strategy has the advantage of eliciting immune responses through different mechanisms and therefore may be superior to homologous prime-boost strategies for generating durable tetravalent immunity. METHODS: In this phase 1 first-in-human heterologous prime-boost study, 80 volunteers were assigned to 4 groups and received a tetravalent dengue virus (DENV-1-4) purified inactivated vaccine (TDENV-PIV) with alum adjuvant and a tetravalent dengue virus (DENV-1-4) live attenuated vaccine (TDENV-LAV) in different orders and dosing schedules (28 or 180 days apart). RESULTS: All vaccination regimens had acceptable safety profiles and there were no vaccine-related serious adverse events. TDEN-PIV followed by TDEN-LAV induced higher neutralizing antibody titers and a higher rate of tetravalent seroconversions compared to TDEN-LAV followed by TDEN-PIV. Both TDEN-PIV followed by TDEN-LAV groups demonstrated 100% tetravalent seroconversion 28 days following the booster dose, which was maintained for most of these subjects through the day 180 measurement. CONCLUSIONS: A heterologous prime-boost vaccination strategy for dengue merits additional evaluation for safety, immunogenicity, and potential for clinical benefit. CLINICAL TRIALS REGISTRATION: NCT02239614.
引用
- Lin L, Koren MA, Paolino KM, et al. Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial. J Infect Dis. 2021. PMID: 32966573. doi:10.1093/infdis/jiaa603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。